INSMED INC Lease, Cost
INSMED INC (INSM) reported Lease, Cost of $40.36 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-19
- INSMED INC lease, cost for the quarter ending 2020-12-31 was $10.94M, a 9.02% increase year-over-year.
- INSMED INC lease, cost for the quarter ending 2020-09-30 was $1.57M.
- INSMED INC lease, cost for the quarter ending 2020-06-30 was $4.87M.
- INSMED INC lease, cost for the quarter ending 2020-03-31 was $3.61M, a 17.15% increase year-over-year.
- INSMED INC lease, cost for fiscal 2025 was $40.36M, a 1.98% decline from fiscal 2024.
- INSMED INC lease, cost for fiscal 2024 was $41.17M, a 38.81% increase from fiscal 2023.
- INSMED INC lease, cost for fiscal 2023 was $29.66M, a 6.16% increase from fiscal 2022.
- INSMED INC lease, cost for fiscal 2022 was $27.94M, a 29.69% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $40.36M 10-K · filed 2026-02-19 | ||||
| 2024-12-31 | $41.17M 10-K · filed 2026-02-19 | ||||
| 2023-12-31 | $29.66M 10-K · filed 2025-02-20 | ||||
| 2022-12-31 | $27.94M 10-K · filed 2024-02-22 | ||||
| 2021-12-31 | $21.55M 10-K · filed 2023-02-23 | ||||
| 2020-12-31 | $10.94M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $12.52M derived: sum of 2 quarters · filed 2022-02-17 | $17.39M derived: sum of 3 quarters · filed 2022-02-17 | $20.99M 10-K · filed 2022-02-17 | |
| 2020-09-30 | $1.57M 10-Q · filed 2020-10-29 | $6.44M derived: sum of 2 quarters · filed 2020-10-29 | $10.05M 10-Q · filed 2020-10-29 | $20.09M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-06-30 | $4.87M 10-Q · filed 2020-08-06 | $8.48M 10-Q · filed 2020-08-06 | $18.52M derived: sum of 3 quarters · filed 2021-02-25 | $18.51M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-03-31 | $3.61M 10-Q · filed 2020-04-30 | $13.64M derived: sum of 2 quarters · filed 2021-02-25 | $13.64M derived: sum of 3 quarters · filed 2021-02-25 | $13.64M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-12-31 | $10.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $10.04M derived: sum of 2 quarters · filed 2021-02-25 | $10.03M derived: sum of 3 quarters · filed 2021-02-25 | $13.11M 10-K · filed 2021-02-25 | $13.02M 10-K · filed 2020-02-25 |
| 2019-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | -$6.00K derived: sum of 2 quarters · filed 2019-10-30 | $3.07M 10-Q · filed 2019-10-30 | ||
| 2019-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $3.08M 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $3.08M 10-Q · filed 2019-05-07 | ||||
| 2018-09-30 | $3.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $9.22M 10-Q · filed 2019-10-30 | |||
| 2018-06-30 | $6.15M 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |